[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.124.106. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 11, 1980

Neonatal Hyperglycemia Following Maternal Diazoxide Administration

Author Affiliations

From the Department of Pharmacy (Dr Milsap) and the Perinatology Center, Department of Pediatrics (Dr Auld), The New York Hospital-Cornell Medical Center, New York.

JAMA. 1980;243(2):144-145. doi:10.1001/jama.1980.03300280042026
Abstract

DIAZOXIDE, a nondiuretic thiazide, when injected intravenously (IV) is a potent arteriolar dilator effective in the treatment of severe hypertension associated with pregnancy.1,2 Animal studies have shown that diazoxide crosses the placenta, causing fetal hyperglycemia3,4 and destruction of pancreatic islet cells.5 An infant experienced severe persistent postnatal hyperglycemia after in utero exposure to diazoxide.

Report of a Case  A 31-year-old woman, gravida 1, para 0, noted to have proteinuria (2+) and blood pressure (BP) of 130/90 mm Hg at approximately 30 weeks' gestation, was hospitalized at 33 weeks with complaints of abdominal pain. A BP of 200/130 mm Hg, with 3+ reflexes, ankle edema, and proteinuria (3+) were present. Mild uterine contractions ensued, with BP to 240/140 mm Hg. The mother was initially treated with intramuscular magnesium sulfate and hydralazine hydrochloride, with reduction in BP to 194/130 mm Hg. Approximately 2 1/2 hours before delivery, furosemide, 40

×